Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences (EXAS) will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection test. The results of a study evaluating a new ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...

Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $85 following quarterly ...

Exact Sciences reported third-quarter results that fell short of analyst expectations and cut its guidance for the fourth quarter. The cut, which William Blair analysts called a “shocking ...

Exact Sciences shares last traded at $51.14, with a volume of 4,851,214 shares trading hands. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...

The Detroit Academy of Arts and Sciences plans to move into the former Hutchins Middle ... which many of the plan’s details ...

Although the exact dates of its arrival and discovery are unclear ... to researchers in Purdue University’s Department of ...

Scientists have pinpointed the binding site for low-dose ketamine on NMDA receptors, explaining its fast-acting effects on ...